Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia

A multinational point prevalence study of hospitalised patients

Marcos I. Restrepo, Bettina L. Babu, Luis F. Reyes, James D. Chalmers, Nilam J. Soni, Oriol Sibila, Paola Faverio, Catia Cilloniz, William Rodriguez-Cintron, Stefano Aliberti, V. H. Cambursano, A. Ceccato, J. Chertcoff, F. Lascar, F. Di Tulio, A. C. Díaz, L. de Vedia, M. C. Ganaha, G. Lopardo, A. G. Malberti & 15 others S. Tartara, B. Pereyra, J. P. Stagnaro, F. Lötsch, F. Thalhammer, K. Anseeuw, C. A. Francois, E. Van Braeckel, J. L. Vincent, M. Z. Djimon, S. Salvi, S. Battaglia, M. Carrabba, P. Ceriana, P. Rossi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.

Original languageEnglish
Article number1701190
JournalEuropean Respiratory Journal
Volume52
Issue number2
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Pseudomonas aeruginosa
Pneumonia
Cross-Sectional Studies
Anti-Bacterial Agents
Lung Diseases
Chronic Disease
Pseudomonas Infections
Bronchiectasis
Tracheostomy
Microbial Drug Resistance
Chronic Obstructive Pulmonary Disease
Logistic Models
Regression Analysis
Bacteria
Delivery of Health Care

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia : A multinational point prevalence study of hospitalised patients. / Restrepo, Marcos I.; Babu, Bettina L.; Reyes, Luis F.; Chalmers, James D.; Soni, Nilam J.; Sibila, Oriol; Faverio, Paola; Cilloniz, Catia; Rodriguez-Cintron, William; Aliberti, Stefano; Cambursano, V. H.; Ceccato, A.; Chertcoff, J.; Lascar, F.; Di Tulio, F.; Díaz, A. C.; de Vedia, L.; Ganaha, M. C.; Lopardo, G.; Malberti, A. G.; Tartara, S.; Pereyra, B.; Stagnaro, J. P.; Lötsch, F.; Thalhammer, F.; Anseeuw, K.; Francois, C. A.; Van Braeckel, E.; Vincent, J. L.; Djimon, M. Z.; Salvi, S.; Battaglia, S.; Carrabba, M.; Ceriana, P.; Rossi, P.

In: European Respiratory Journal, Vol. 52, No. 2, 1701190, 01.08.2018.

Research output: Contribution to journalArticle

Restrepo, MI, Babu, BL, Reyes, LF, Chalmers, JD, Soni, NJ, Sibila, O, Faverio, P, Cilloniz, C, Rodriguez-Cintron, W, Aliberti, S, Cambursano, VH, Ceccato, A, Chertcoff, J, Lascar, F, Di Tulio, F, Díaz, AC, de Vedia, L, Ganaha, MC, Lopardo, G, Malberti, AG, Tartara, S, Pereyra, B, Stagnaro, JP, Lötsch, F, Thalhammer, F, Anseeuw, K, Francois, CA, Van Braeckel, E, Vincent, JL, Djimon, MZ, Salvi, S, Battaglia, S, Carrabba, M, Ceriana, P & Rossi, P 2018, 'Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: A multinational point prevalence study of hospitalised patients', European Respiratory Journal, vol. 52, no. 2, 1701190. https://doi.org/10.1183/13993003.01190-2017
Restrepo, Marcos I. ; Babu, Bettina L. ; Reyes, Luis F. ; Chalmers, James D. ; Soni, Nilam J. ; Sibila, Oriol ; Faverio, Paola ; Cilloniz, Catia ; Rodriguez-Cintron, William ; Aliberti, Stefano ; Cambursano, V. H. ; Ceccato, A. ; Chertcoff, J. ; Lascar, F. ; Di Tulio, F. ; Díaz, A. C. ; de Vedia, L. ; Ganaha, M. C. ; Lopardo, G. ; Malberti, A. G. ; Tartara, S. ; Pereyra, B. ; Stagnaro, J. P. ; Lötsch, F. ; Thalhammer, F. ; Anseeuw, K. ; Francois, C. A. ; Van Braeckel, E. ; Vincent, J. L. ; Djimon, M. Z. ; Salvi, S. ; Battaglia, S. ; Carrabba, M. ; Ceriana, P. ; Rossi, P. / Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia : A multinational point prevalence study of hospitalised patients. In: European Respiratory Journal. 2018 ; Vol. 52, No. 2.
@article{faab187470cc4add809aaa1380163fb5,
title = "Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: A multinational point prevalence study of hospitalised patients",
abstract = "Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2{\%} and 2.0{\%}, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67{\%}. In contrast, the rate of P. aeruginosa-CAP was 2{\%} in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.",
author = "Restrepo, {Marcos I.} and Babu, {Bettina L.} and Reyes, {Luis F.} and Chalmers, {James D.} and Soni, {Nilam J.} and Oriol Sibila and Paola Faverio and Catia Cilloniz and William Rodriguez-Cintron and Stefano Aliberti and Cambursano, {V. H.} and A. Ceccato and J. Chertcoff and F. Lascar and {Di Tulio}, F. and D{\'i}az, {A. C.} and {de Vedia}, L. and Ganaha, {M. C.} and G. Lopardo and Malberti, {A. G.} and S. Tartara and B. Pereyra and Stagnaro, {J. P.} and F. L{\"o}tsch and F. Thalhammer and K. Anseeuw and Francois, {C. A.} and {Van Braeckel}, E. and Vincent, {J. L.} and Djimon, {M. Z.} and S. Salvi and S. Battaglia and M. Carrabba and P. Ceriana and P. Rossi",
year = "2018",
month = "8",
day = "1",
doi = "10.1183/13993003.01190-2017",
language = "English",
volume = "52",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "2",

}

TY - JOUR

T1 - Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia

T2 - A multinational point prevalence study of hospitalised patients

AU - Restrepo, Marcos I.

AU - Babu, Bettina L.

AU - Reyes, Luis F.

AU - Chalmers, James D.

AU - Soni, Nilam J.

AU - Sibila, Oriol

AU - Faverio, Paola

AU - Cilloniz, Catia

AU - Rodriguez-Cintron, William

AU - Aliberti, Stefano

AU - Cambursano, V. H.

AU - Ceccato, A.

AU - Chertcoff, J.

AU - Lascar, F.

AU - Di Tulio, F.

AU - Díaz, A. C.

AU - de Vedia, L.

AU - Ganaha, M. C.

AU - Lopardo, G.

AU - Malberti, A. G.

AU - Tartara, S.

AU - Pereyra, B.

AU - Stagnaro, J. P.

AU - Lötsch, F.

AU - Thalhammer, F.

AU - Anseeuw, K.

AU - Francois, C. A.

AU - Van Braeckel, E.

AU - Vincent, J. L.

AU - Djimon, M. Z.

AU - Salvi, S.

AU - Battaglia, S.

AU - Carrabba, M.

AU - Ceriana, P.

AU - Rossi, P.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.

AB - Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.

UR - http://www.scopus.com/inward/record.url?scp=85051459272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051459272&partnerID=8YFLogxK

U2 - 10.1183/13993003.01190-2017

DO - 10.1183/13993003.01190-2017

M3 - Article

VL - 52

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 2

M1 - 1701190

ER -